StockData

Insmed vs Moderna

INSM and MRNA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How INSM and MRNA compare

Moderna is the larger company, worth 3.1 times as much as Insmed ($82.6B against $26.7B).

Insmed grew revenue faster over the last twelve months (240% versus −27.6% for Moderna).

Insmed keeps more of each dollar of sales as profit, with a net margin of −39.9% compared with −141% at Moderna.

Insmed scores higher on the StockData Score (8 against 5 for Moderna), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricINSMMRNA
Size and price
Market cap$26.7B$82.6B
Share price$121.86$206.80
Change, 1 year−36.9%735%
Change, 5 years321%−37.3%
Beta (5Y)0.84−0.29
Employees1,6644,700
StockData Score
Total score8 (better)5
Valuation score00
Growth score3 (better)1
Performance score2 (better)1
Health score33
Dividend score00
Valuation
P/S17.6× (better)37.1×
P/B36.8×12.2× (better)
FCF yield−2.3%−1.5% (better)
Fair value$61.10$32.48
Margin of safety−99.5% (better)−537%
Growth
Revenue growth (TTM)240% (better)−27.6%
Revenue growth, 5Y average29.8% (better)19.3%
Profitability
Gross margin84.4% (better)23.4%
Operating margin−37.1% (better)−149%
Net margin−39.9% (better)−141%
FCF margin−41.3% (better)−55.8%
Return on equity−72.5%−39.0% (better)
Return on invested capital–−80.9%
Financial health
Debt / equity0.760.09 (better)
Interest coverage−6.9×–
Current ratio2.86 (better)2.29
Altman Z-score7.4212.01 (better)
Piotroski F-score4 (better)3
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions102%79.9%
Held by insiders0.89%5.6%
Insider net buying, 12 months−$133M−$81.6M (better)
Superinvestors holding1–
Short interest, % of float6.5%8.8%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.